

Express Mail Label No.

Dated: _____

Docket No.: 03939/100M269-US1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**In re Patent Application of:
Daniel A. Moros**

Application No.: 10/735,514

Confirmation No.: 1588

Filed: December 11, 2003

Art Unit: N/A

For: METHOD OF TREATING MOVEMENT
DISORDERS USING BARBITURIC ACID
DERIVATIVES

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, attached hereto is a copy of Form PTO/SB/08 and copies of the documents listed thereon.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO/SB/08) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO/SB/08 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application. This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Registration No.: 50,239
DARBY & DARBY P.C.
P.O. Box 5257
New York, New York 10150-5257
(212) 527-7700
(212) 753-6237 (Fax)
Attorneys/Agents For Applicant



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	2	Attorney Docket Number	03939/100M269-US1
-------	---	----	---	------------------------	-------------------

Complete if Known

Application Number	10/735,514
Filing Date	December 11, 2003
First Named Inventor	Daniel A. Moros
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	03939/100M269-US1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	1	US-6,281,207	08-28-2001	Richter et al.	entire document
	2	US-6,093,820	07-25-2000	Gutman et al.	entire document
	3	US-5,985,856	11-16-1999	Stella et al.	entire document
	4	US-5,456,851	10-10-1995	Liu et al.	entire document
	5	US-4,628,056	12-09-1986	Levitt et al.	entire document
	6	US-4,260,769	04-07-1981	Stella et al.	entire document
	7	US-3,679,683	07-25-1972	Gorbaty	entire document

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	8	WO 03/063872 A1 ✓	08-07-2003	Taro Pharmaceutical Industries Ltd.	entire document	
	9	WO 01/79185 A1 ✓	10-25-2001	Kenneth Curry	entire document	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	10	Rev. Neurol, 2001, 32 (6): 520-524; I. Balas et al. "Talamotomia estereotaxica de la enfermedad de Parkinson y otros tipos de temblor. Experiencias de la actividad multiunitaria burst en el talamo basada en semimicroelectrodos". (English Abstract)	
	11	Clinician, May 2001, Vol. 19, No. 2, pp. 1-15, "Essential Tremor: A Practical Guide to Evaluation, Diagnosis, and Treatment".	
	12	Movement Disorders, Vol. 16, No. 3, 2001 pp 464-468, William C. Koller, et al. "Long Term Safety and Efficacy of Unilateral Deep Brain Stimulation of the Thalamus in Essential Tremor".	
	13	The New England Journal of Medicine, Vol. 345, No. 12, Sept. 2001 pp 887-891, Elan D. Louis, "Essential Tremor".	
	14	Neurology, June 2000, Vol. 54, Suppl 4, S8-S13, Leslie J. Findley, "Epidemiology and Genetics of Essential Tremor".	
	15	Neurology, June 2000 Vol. 54, Suppl 4, S30-S38, William C. Koller et al., "Pharmacologic Treatment of Essential Tremor"	
	16	Archives of Neurology, April 1999, Vol. 56, No. 4: 475-480, Alexandre Gironell, et al., "A Randomized Placebo-Controlled Comparative Trial of Gabapentin and Propranolol in Essential Tremor".	

Signature		Date Considered	
-----------	--	-----------------	--



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/735,514
				Filing Date	December 11, 2003
				First Named Inventor	Daniel A. Moros
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	03939/100M269-US1

	17	The New England Journal of Medicine, Vol. 339, No. 16, Oct. 1998, pp. 1130-1143, Anthony E. Lang, et al. "Parkinson's Disease", Second of Two Parts.	
	18	Movement Disorders, Vol. 13, Suppl 3., pp 90-100, 1998, Paul G. Wasielewski, et al. "Pharmacologic Treatment of Tremor".	
	19	Mayo Clinic Proceedings, Vol. 66, No. 10, Oct. 1991, pp. 991-997, Manfred D. Muentner, et al. "Treatment of Essential Tremor With Methazolamide".	
	20	Parkinson's Disease and Movement Disorders, Urban & Schwarzenberg, Inc., 1988, 17: 225-234, Stanley Fahn, et al. "Clinical Rating Scale for Tremor"	
	21	Movement Disorders 2, 1987, (22) 438-458, Leslie J. Findley, "The Pharmacology of Essential Tremor".	
	22	Modern Pharmacology, 2nd Ed., 1986, Ch. 4, pp. 41-64, Theodore E. Gram "Metabolism of Drugs".	
	23	Journal of Neurology, Neurosurgery, and Psychiatry, 1985; 48, No. 9, 911-915, Leslie J. Findley et al., "Primidone in Essential Tremor of the Hands and Head: A Double Blind Controlled Clinical Study".	
	24	C.D. Marsden, Origins of Normal and Pathological Tremor in Movement Disorders : <i>Tremor</i> . Eds. L.J. Findley and R. Capildeo, New York. Oxford University Press, 1984, pp 37-84 "Origins of Normal and Pathological Tremor".	
	25	Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed. Ch. 17, 361-396, William R. Hobbs et al., "Hypnotics and Sedatives; Ethanol".	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Signature		Date Considered	
-----------	--	-----------------	--



Application No. (if known): 10/735,514

Attorney Docket No.: 03939/100M269-US1

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. _____ in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

EV 418266662-US

on May 24, 2004
Date

B.W. Lee

Signature

B.W. LEE

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

assmt.
decl.

IDS (Citation) by Applicant (List of References) (2 pages);

Information Disclosure Statement (2 pages);

Transmittal Form (1 page);

Fee Transmittal Letter (1 page);

Response to Notice to File Missing Parts of Application (2 pages);

Postcard (1 page);

Check No. 5065 for \$2,520.00.

A copy of the Notice to File Missing Parts